A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
Rafic Hariri University Hospital
Beirut, Lebanon
RECRUITINGIncrease in High-Density Lipoprotein (HDL)
Time frame: Change from Baseline in High-Density Lipoprotein (HDL) at 3 months
changes of liver enzymes
Time frame: Baseline and 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.